Monument Therapeutics Partners with FNIH for Innovative Schizophrenia Treatment Clinical Trial Monument Therapeutics collaborates with the Foundation for NIH to explore a groundbreaking treatment for cognitive issues in schizophrenia, MT1988.

Monument Therapeutics Partners with FNIH for Innovative Schizophrenia Treatment Clinical Trial #United_Kingdom #Manchester #Monument_Therapeutics #FNIH #MT1988

Monument Therapeutics Strengthens Leadership with New Chair and Advisory Board Members Monument Therapeutics announces the appointment of Robert Radie as Chair and Heather Preston to its advisory board, enhancing its leadership team.

Monument Therapeutics Strengthens Leadership with New Chair and Advisory Board Members #United_Kingdom #Manchester #Monument_Therapeutics #Robert_Radie #Heather_Preston